USE OF IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS

• US 20120308566A1
• Filed: 10/12/2010
• Published: 12/06/2012
• Est. Priority Date: 10/12/2009
• Status: Abandoned Application

• Current Assignee: Kirin-Amgen Inc. (Amgen Inc.)
• Original Assignee: Amgen Inc.
• Inventors: Martin, David Andrew, Tocker, Joel, Baumgartner, Scott, Franko, Donna Christine
• Application Number:
  US13/501,430
• Publication Number:
  US 20120308566A1
• Time in Patent Office: Days
• US Class Current: 424/135.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/567 Framework region [FR]
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for treating diseases, such as various forms of cancer.

Claims

1. A method of treating cancer in a patient in need thereof, comprising administering to said patient an effective amount of a composition comprising an antibody that specifically binds human IL-17 Receptor A and inhibits the binding of IL-17A, wherein said antibody is selected from the group consisting of:

A.

a. a light chain variable domain sequence that is at least 80% identical to a light chain variable domain sequence of AM_L1-26 (SEQ ID NOs;

27-53, respectively);

b. a heavy chain variable domain sequence that is at least 80% identical to a heavy chain variable domain sequence of AM_H1-26 (SEQ ID NOs;

1-26, respectively);

or

c. the light chain variable domain of (a) and the heavy chain variable domain of (b); and

B. a light chain CDR1, CDR2, CDR3 and a heavy chain CDR1, CDR2, CDR3 that differs by no more than a total of three amino acid additions, substitutions, and/or deletions in each CDR from the following sequences;

a. a light chain CDR1 (SEQ ID NO;

185), CDR2 (SEQ ID NO;

186), CDR3 (SEQ ID NO;

187) and a heavy chain CDR1 (SEQ ID NO;

107), CDR2 (SEQ ID NO;

108), CDR3 (SEQ ID NO;

109) of antibody AM-1;

b. a light chain CDR1 (SEQ ID NO;

188), CDR2 (SEQ ID NO;

189), CDR3 (SEQ ID NO;

190) and a heavy chain CDR1 (SEQ ID NO;

110), CDR2 (SEQ ID NO;

111), CDR3 (SEQ ID NO;

112) of antibody AM-2;

c. a light chain CDR1 (SEQ ID NO;

191), CDR2 (SEQ ID NO;

192), CDR3 (SEQ ID NO;

193) and a heavy chain CDR1 (SEQ ID NO;

113), CDR2 (SEQ ID NO;

114), CDR3 (SEQ ID NO;

115) of antibody AM-3;

d. a light chain CDR1 (SEQ ID NO;

194), CDR2 (SEQ ID NO;

195), CDR3 (SEQ ID NO;

196) and a heavy chain CDR1 (SEQ ID NO;

116), CDR2 (SEQ ID NO;

117), CDR3 (SEQ ID NO;

118) of antibody AM-4;

e. a light chain CDR1 (SEQ ID NO;

197), CDR2 (SEQ ID NO;

198), CDR3 (SEQ ID NO;

199) and a heavy chain CDR1 (SEQ ID NO;

119), CDR2 (SEQ ID NO;

120), CDR3 (SEQ ID NO;

121) of antibody AM-5;

f. a light chain CDR1 (SEQ ID NO;

200), CDR2 (SEQ ID NO;

201), CDR3 (SEQ ID NO;

202) and a heavy chain CDR1 (SEQ ID NO;

122), CDR2 (SEQ ID NO;

123), CDR3 (SEQ ID NO;

124) of antibody AM-6;

g. a light chain CDR1 (SEQ ID NO;

203), CDR2 (SEQ ID NO;

204), CDR3 (SEQ ID NO;

205) and a heavy chain CDR1 (SEQ ID NO;

125), CDR2 (SEQ ID NO;

126), CDR3 (SEQ ID NO;

127) of antibody AM-7;

h. a light chain CDR1 (SEQ ID NO;

206), CDR2 (SEQ ID NO;

207), CDR3 (SEQ ID NO;

208) and a heavy chain CDR1 (SEQ ID NO;

128), CDR2 (SEQ ID NO;

129), CDR3 (SEQ ID NO;

130) of antibody AM-8;

i. a light chain CDR1 (SEQ ID NO;

209), CDR2 (SEQ ID NO;

210), CDR3 (SEQ ID NO;

211) and a heavy chain CDR1 (SEQ ID NO;

131), CDR2 (SEQ ID NO;

132), CDR3 (SEQ ID NO;

133) of antibody AM-9;

j. a light chain CDR1 (SEQ ID NO;

212), CDR2 (SEQ ID NO;

213), CDR3 (SEQ ID NO;

214) and a heavy chain CDR1 (SEQ ID NO;

134), CDR2 (SEQ ID NO;

135), CDR3 (SEQ ID NO;

136) of antibody AM-10;

k. a light chain CDR1 (SEQ ID NO;

215), CDR2 (SEQ ID NO;

216), CDR3 (SEQ ID NO;

217) and a heavy chain CDR1 (SEQ ID NO;

137), CDR2 (SEQ ID NO;

138), CDR3 (SEQ ID NO;

139) of antibody AM-11;

l. a light chain CDR1 (SEQ ID NO;

218), CDR2 (SEQ ID NO;

219), CDR3 (SEQ ID NO;

220) and a heavy chain CDR1 (SEQ ID NO;

140), CDR2 (SEQ ID NO;

141), CDR3 (SEQ ID NO;

142) of antibody AM-12;

m. a light chain CDR1 (SEQ ID NO;

221), CDR2 (SEQ ID NO;

222), CDR3 (SEQ ID NO;

223) and a heavy chain CDR1 (SEQ ID NO;

143), CDR2 (SEQ ID NO;

144), CDR3 (SEQ ID NO;

145) of antibody AM-13;

n. a light chain CDR1 (SEQ ID NO;

224), CDR2 (SEQ ID NO;

225), CDR3 (SEQ ID NO;

226) and a heavy chain CDR1 (SEQ ID NO;

146), CDR2 (SEQ ID NO;

147), CDR3 (SEQ ID NO;

148) of antibody AM-14;

o. a light chain CDR1 (SEQ ID NO;

227), CDR2 (SEQ ID NO;

228), CDR3 (SEQ ID NO;

229) and a heavy chain CDR1 (SEQ ID NO;

149), CDR2 (SEQ ID NO;

150), CDR3 (SEQ ID NO;

151) of antibody AM-15;

p. a light chain CDR1 (SEQ ID NO;

230), CDR2 (SEQ ID NO;

231), CDR3 (SEQ ID NO;

232) and a heavy chain CDR1 (SEQ ID NO;

152), CDR2 (SEQ ID NO;

153), CDR3 (SEQ ID NO;

154) of antibody AM-16;

q. a light chain CDR1 (SEQ ID NO;

233), CDR2 (SEQ ID NO;

234), CDR3 (SEQ ID NO;

235) and a heavy chain CDR1 (SEQ ID NO;

155), CDR2 (SEQ ID NO;

156), CDR3 (SEQ ID NO;

157) of antibody AM-17;

r. a light chain CDR1 (SEQ ID NO;

236), CDR2 (SEQ ID NO;

237), CDR3 (SEQ ID NO;

238) and a heavy chain CDR1 (SEQ ID NO;

158), CDR2 (SEQ ID NO;

159), CDR3 (SEQ ID NO;

160) of antibody AM-18;

s. a light chain CDR1 (SEQ ID NO;

239), CDR2 (SEQ ID NO;

240), CDR3 (SEQ ID NO;

241) and a heavy chain CDR1 (SEQ ID NO;

161), CDR2 (SEQ ID NO;

162), CDR3 (SEQ ID NO;

163) of antibody AM-19;

t. a light chain CDR1 (SEQ ID NO;

242), CDR2 (SEQ ID NO;

243), CDR3 (SEQ ID NO;

244) and a heavy chain CDR1 (SEQ ID NO;

164), CDR2 (SEQ ID NO;

165), CDR3 (SEQ ID NO;

166) of antibody AM-20;

u. a light chain CDR1 (SEQ ID NO;

245), CDR2 (SEQ ID NO;

246), CDR3 (SEQ ID NO;

247) and a heavy chain CDR1 (SEQ ID NO;

167), CDR2 (SEQ ID NO;

168), CDR3 (SEQ ID NO;

169) of antibody AM-21;

v. a light chain CDR1 (SEQ ID NO;

248), CDR2 (SEQ ID NO;

249), CDR3 (SEQ ID NO;

250) and a heavy chain CDR1 (SEQ ID NO;

170), CDR2 (SEQ ID NO;

171), CDR3 (SEQ ID NO;

172) of antibody AM-22;

w. a light chain CDR1 (SEQ ID NO;

251), CDR2 (SEQ ID NO;

252), CDR3 (SEQ ID NO;

253) and a heavy chain CDR1 (SEQ ID NO;

173), CDR2 (SEQ ID NO;

174), CDR3 (SEQ ID NO;

175) of antibody AM-23;

x. a light chain CDR1 (SEQ ID NO;

254), CDR2 (SEQ ID NO;

255), CDR3 (SEQ ID NO;

256) and a heavy chain CDR1 (SEQ ID NO;

173), CDR2 (SEQ ID NO;

174), CDR3 (SEQ ID NO;

175) of antibody AM-23;

y. a light chain CDR1 (SEQ ID NO;

257), CDR2 (SEQ ID NO;

258), CDR3 (SEQ ID NO;

259) and a heavy chain CDR1 (SEQ ID NO;

176), CDR2 (SEQ ID NO;

177), CDR3 (SEQ ID NO;

178) of antibody AM-24;

z. a light chain CDR1 (SEQ ID NO;

260), CDR2 (SEQ ID NO;

261), CDR3 (SEQ ID NO;

262) and a heavy chain CDR1 (SEQ ID NO;

179), CDR2 (SEQ ID NO;

180), CDR3 (SEQ ID NO;

181) of antibody AM-25;

or

z.2. a light chain CDR1 (SEQ ID NO;

263), CDR2 (SEQ ID NO;

264), CDR3 (SEQ ID NO;

265) and a heavy chain CDR1 (SEQ ID NO;

182), CDR2 (SEQ ID NO;

183), CDR3 (SEQ ID NO;

184) of antibody AM-26;

wherein said polypeptide specifically binds IL-17 receptor A.

2. The method of claim 1, wherein said antibody comprises:

a. a heavy chain CDR1 comprising an amino acid sequence selected from the group consisting of;

i. X₁YGIS, wherein X₁ is selected from the group consisting of R, S and G;

b. a heavy chain CDR2 comprising an amino acid sequence selected from the group consisting of;

i. WISX₁YX₂GNTX₃YAQX₄X₅QG, wherein X₁ is selected from the group consisting of A, X₂ is selected from the group consisting of N, S and K, X₃ is selected from the group consisting of N and K, X₄ is selected from the group consisting of K and N, and X₅ is selected from the group consisting of L and F;

c. a heavy chain CDR3 comprising an amino acid sequence selected from the group consisting of;

i. X₁QLX₂X₃DY, wherein X₁ is selected from the group consisting of R and K, X₂ is selected from the group consisting of Y, V, and A, and X₃ is selected from the group consisting of F and L;

ii. X₁QLX₂FDY, wherein X₁ is selected from the group consisting of R and K, and X₂ is selected from the group consisting of Y and V;

d. a light chain CDR1 comprising an amino acid sequence selected from the group consisting of;

i. RASQSX₁X₂X₃X₄LA, wherein X₁ is selected from the group consisting of V and I, X₂ is selected from the group consisting of I and S, X₃ is selected from the group consisting of S and T, X₄ is selected from the group consisting of N and S, and X₅ is selected from the group consisting of A and N, and

ii. RASQSX₁SSNLA, wherein X₁ is selected from the group consisting of V and I;

e. a light chain CDR2 comprising an amino acid sequence selected from the group consisting of;

i. X₁X₂STRAX₃, wherein X₁ is selected from the group consisting of G and D, X₂ is selected from the group consisting of A and T, and X₃ is selected from the group consisting of T and A, and

ii. X₁ASTRAX₂, wherein X₁ is selected from the group consisting of G and D, and X₂ is selected from the group consisting of A and T; and

f. a light chain CDR3 comprising an amino acid sequence selected from the group consisting of;

i. QQYDX₁WPLT, wherein X₁ is selected from the group consisting of N, T, and I;

wherein said antibody specifically binds IL-17 receptor A.

3. The method of claim 2, wherein said antibody comprises:

a. a heavy chain CDR1 amino acid sequence comprising X₁YGIS, wherein X₁ is selected from the group consisting of R, S and G;

b. a heavy chain CDR2 amino acid sequence comprising WISX₁YX₂GNTX₃YAQX₄X₅QG, wherein X₁ is selected from the group consisting of A, X₂ is selected from the group consisting of N, S and K, X₃ is selected from the group consisting of N and K, X₄ is selected from the group consisting of K and N, and X₅ is selected from the group consisting of L and F;

c. a heavy chain CDR3 amino acid sequence comprising X₁QLX₂FDY, wherein X₁ is selected from the group consisting of R and K, and X₂ is selected from the group consisting of Y and V;

d. a light chain CDR1 amino acid sequence comprising RASQSX₁SSNLA, wherein X₁ is selected from the group consisting of V and I;

e. a light chain CDR2 amino acid sequence comprising X₁ASTRAX₂, wherein X₁ is selected from the group consisting of G and D, and X₂ is selected from the group consisting of A and T; and

f. a light chain CDR3 amino acid sequence comprising QQYDX₁WPLT, wherein X₁ is selected from the group consisting of N, T, and I;

wherein said antibody specifically binds IL-17 receptor A.

4. The method of claim 1, wherein said antibody comprises:

a. a light chain variable domain and a heavy chain variable domain of AM_L1/AM_H1 (SEQ ID NO;

27/SEQ ID NO;

1);

b. a light chain variable domain and a heavy chain variable domain of AM_L2/AM_H2 (SEQ ID NO;

28/SEQ ID NO;

2);

c. a light chain variable domain and a heavy chain variable domain of AM_L3/AM_H3 (SEQ ID NO;

29/SEQ ID NO;

3);

d. a light chain variable domain and a heavy chain variable domain of AM_L4/AM_H4 (SEQ ID NO;

30/SEQ ID NO;

4);

e. a light chain variable domain and a heavy chain variable domain of AM_L5/AM_H5 (SEQ ID NO;

31/SEQ ID NO;

5);

f. a light chain variable domain and a heavy chain variable domain of AM_L6/AM_H6 (SEQ ID NO;

32/SEQ ID NO;

6)

g. a light chain variable domain and a heavy chain variable domain of AM_L7/AM_H7 (SEQ ID NO;

33/SEQ ID NO;

7);

h. a light chain variable domain and a heavy chain variable domain of AM_L8/AM_H8 (SEQ ID NO;

34/SEQ ID NO;

8);

i. a light chain variable domain and a heavy chain variable domain of AM_L9/AM_H9 (SEQ ID NO;

35/SEQ ID NO;

9);

j. a light chain variable domain and a heavy chain variable domain of AM_L10/AM_H10 (SEQ ID NO;

36/SEQ ID NO;

10);

k. a light chain variable domain and a heavy chain variable domain of AM_L11/AM_H11 (SEQ ID NO;

37/SEQ ID NO;

11);

l. a light chain variable domain and a heavy chain variable domain of AM_L12/AM_H12 (SEQ ID NO;

38/SEQ ID NO;

12);

m. a light chain variable domain and a heavy chain variable domain of AM_L13/AM_H13 (SEQ ID NO;

39/SEQ ID NO;

13);

n. a light chain variable domain and a heavy chain variable domain of AM_L14/AM_H14 (SEQ ID NO;

40/SEQ ID NO;

14);

o. a light chain variable domain and a heavy chain variable domain of AM_L15/AM_H15 (SEQ ID NO;

41/SEQ ID NO;

15);

p. a light chain variable domain and a heavy chain variable domain of AM_L16/AM_H16 (SEQ ID NO;

42/SEQ ID NO;

16);

q. a light chain variable domain and a heavy chain variable domain of AM_L17/AM_H17 (SEQ ID NO;

43/SEQ ID NO;

17);

r. a light chain variable domain and a heavy chain variable domain of AM_L18/AM_H18 (SEQ ID NO;

44/SEQ ID NO;

18);

s. a light chain variable domain and a heavy chain variable domain of AM_L19/AM_H19 (SEQ ID NO;

45/SEQ ID NO;

19);

t. a light chain variable domain and a heavy chain variable domain of AM_L20/AM_H20 (SEQ ID NO;

46/SEQ ID NO;

20);

u. a light chain variable domain and a heavy chain variable domain of AM_L21/AM_H21 (SEQ ID NO;

47/SEQ ID NO;

21);

v. a light chain variable domain and a heavy chain variable domain of AM_L22/AM_H22 (SEQ ID NO;

48/SEQ ID NO;

22);

w. a light chain variable domain and a heavy chain variable domain of AM_L23/AM_H23 (SEQ ID NO;

49 or SEQ ID NO;

50/SEQ ID NO;

23);

x. a light chain variable domain and a heavy chain variable domain of AM_L24/AM_H24 (SEQ ID NO;

51/SEQ ID NO;

24);

y. a light chain variable domain and a heavy chain variable domain of AM_L25/AM_H25 (SEQ ID NO;

52/SEQ ID NO;

25); and

z. a light chain variable domain and a heavy chain variable domain of AM_L26/AM_H26 (SEQ ID NO;

53/SEQ ID NO;

26);

wherein said polypeptide specifically binds IL-17 receptor A.

5. The method of claim 1, wherein said antibody comprises:

a. a light chain CDR1 (SEQ ID NO;

185), CDR2 (SEQ ID NO;

186), CDR3 (SEQ ID NO;

187) and a heavy chain CDR1 (SEQ ID NO;

107), CDR2 (SEQ ID NO;

108), CDR3 (SEQ ID NO;

109) of antibody AM-1;

b. a light chain CDR1 (SEQ ID NO;

188), CDR2 (SEQ ID NO;

189), CDR3 (SEQ ID NO;

190) and a heavy chain CDR1 (SEQ ID NO;

110), CDR2 (SEQ ID NO;

111), CDR3 (SEQ ID NO;

112) of antibody AM-2;

c. a light chain CDR1 (SEQ ID NO;

191), CDR2 (SEQ ID NO;

192), CDR3 (SEQ ID NO;

193) and a heavy chain CDR1 (SEQ ID NO;

113), CDR2 (SEQ ID NO;

114), CDR3 (SEQ ID NO;

115) of antibody AM-3;

d. a light chain CDR1 (SEQ ID NO;

194), CDR2 (SEQ ID NO;

195), CDR3 (SEQ ID NO;

196) and a heavy chain CDR1 (SEQ ID NO;

116), CDR2 (SEQ ID NO;

117), CDR3 (SEQ ID NO;

118) of antibody AM-4;

e. a light chain CDR1 (SEQ ID NO;

197), CDR2 (SEQ ID NO;

198), CDR3 (SEQ ID NO;

199) and a heavy chain CDR1 (SEQ ID NO;

119), CDR2 (SEQ ID NO;

120), CDR3 (SEQ ID NO;

121) of antibody AM-5;

f. a light chain CDR1 (SEQ ID NO;

200), CDR2 (SEQ ID NO;

201), CDR3 (SEQ ID NO;

202) and a heavy chain CDR1 (SEQ ID NO;

122), CDR2 (SEQ ID NO;

123), CDR3 (SEQ ID NO;

124) of antibody AM-6;

g. a light chain CDR1 (SEQ ID NO;

203), CDR2 (SEQ ID NO;

204), CDR3 (SEQ ID NO;

205) and a heavy chain CDR1 (SEQ ID NO;

125), CDR2 (SEQ ID NO;

126), CDR3 (SEQ ID NO;

127) of antibody AM-7;

h. a light chain CDR1 (SEQ ID NO;

206), CDR2 (SEQ ID NO;

207), CDR3 (SEQ ID NO;

208) and a heavy chain CDR1 (SEQ ID NO;

128), CDR2 (SEQ ID NO;

129), CDR3 (SEQ ID NO;

130) of antibody AM-8;

i. a light chain CDR1 (SEQ ID NO;

209), CDR2 (SEQ ID NO;

210), CDR3 (SEQ ID NO;

211) and a heavy chain CDR1 (SEQ ID NO;

131), CDR2 (SEQ ID NO;

132), CDR3 (SEQ ID NO;

133) of antibody AM-9;

j. a light chain CDR1 (SEQ ID NO;

212), CDR2 (SEQ ID NO;

213), CDR3 (SEQ ID NO;

214) and a heavy chain CDR1 (SEQ ID NO;

134), CDR2 (SEQ ID NO;

135), CDR3 (SEQ ID NO;

136) of antibody AM-10;

k. a light chain CDR1 (SEQ ID NO;

215), CDR2 (SEQ ID NO;

216), CDR3 (SEQ ID NO;

217) and a heavy chain CDR1 (SEQ ID NO;

137), CDR2 (SEQ ID NO;

138), CDR3 (SEQ ID NO;

139) of antibody AM-11;

l. a light chain CDR1 (SEQ ID NO;

218), CDR2 (SEQ ID NO;

219), CDR3 (SEQ ID NO;

220) and a heavy chain CDR1 (SEQ ID NO;

140), CDR2 (SEQ ID NO;

141), CDR3 (SEQ ID NO;

142) of antibody AM-12;

m. a light chain CDR1 (SEQ ID NO;

221), CDR2 (SEQ ID NO;

222), CDR3 (SEQ ID NO;

223) and a heavy chain CDR1 (SEQ ID NO;

143), CDR2 (SEQ ID NO;

144), CDR3 (SEQ ID NO;

145) of antibody AM-13;

n. a light chain CDR1 (SEQ ID NO;

224), CDR2 (SEQ ID NO;

225), CDR3 (SEQ ID NO;

226) and a heavy chain CDR1 (SEQ ID NO;

146), CDR2 (SEQ ID NO;

147), CDR3 (SEQ ID NO;

148) of antibody AM-14;

o. a light chain CDR1 (SEQ ID NO;

227), CDR2 (SEQ ID NO;

228), CDR3 (SEQ ID NO;

229) and a heavy chain CDR1 (SEQ ID NO;

149), CDR2 (SEQ ID NO;

150), CDR3 (SEQ ID NO;

151) of antibody AM-15;

p. a light chain CDR1 (SEQ ID NO;

230), CDR2 (SEQ ID NO;

231), CDR3 (SEQ ID NO;

232) and a heavy chain CDR1 (SEQ ID NO;

152), CDR2 (SEQ ID NO;

153), CDR3 (SEQ ID NO;

154) of antibody AM-16;

q. a light chain CDR1 (SEQ ID NO;

233), CDR2 (SEQ ID NO;

234), CDR3 (SEQ ID NO;

235) and a heavy chain CDR1 (SEQ ID NO;

155), CDR2 (SEQ ID NO;

156), CDR3 (SEQ ID NO;

157) of antibody AM-17;

r. a light chain CDR1 (SEQ ID NO;

236), CDR2 (SEQ ID NO;

237), CDR3 (SEQ ID NO;

238) and a heavy chain CDR1 (SEQ ID NO;

158), CDR2 (SEQ ID NO;

159), CDR3 (SEQ ID NO;

160) of antibody AM-18;

s. a light chain CDR1 (SEQ ID NO;

239), CDR2 (SEQ ID NO;

240), CDR3 (SEQ ID NO;

241) and a heavy chain CDR1 (SEQ ID NO;

161), CDR2 (SEQ ID NO;

162), CDR3 (SEQ ID NO;

163) of antibody AM-19;

t. a light chain CDR1 (SEQ ID NO;

242), CDR2 (SEQ ID NO;

243), CDR3 (SEQ ID NO;

244) and a heavy chain CDR1 (SEQ ID NO;

164), CDR2 (SEQ ID NO;

165), CDR3 (SEQ ID NO;

166) of antibody AM-20;

u. a light chain CDR1 (SEQ ID NO;

245), CDR2 (SEQ ID NO;

246), CDR3 (SEQ ID NO;

247) and a heavy chain CDR1 (SEQ ID NO;

167), CDR2 (SEQ ID NO;

168), CDR3 (SEQ ID NO;

169) of antibody AM-21;

v. a light chain CDR1 (SEQ ID NO;

248), CDR2 (SEQ ID NO;

249), CDR3 (SEQ ID NO;

250) and a heavy chain CDR1 (SEQ ID NO;

170), CDR2 (SEQ ID NO;

171), CDR3 (SEQ ID NO;

172) of antibody AM-22;

w. a light chain CDR1 (SEQ ID NO;

251), CDR2 (SEQ ID NO;

252), CDR3 (SEQ ID NO;

253) and a heavy chain CDR1 (SEQ ID NO;

173), CDR2 (SEQ ID NO;

174), CDR3 (SEQ ID NO;

175) of antibody AM-23;

x. a light chain CDR1 (SEQ ID NO;

254), CDR2 (SEQ ID NO;

255), CDR3 (SEQ ID NO;

256) and a heavy chain CDR1 (SEQ ID NO;

173), CDR2 (SEQ ID NO;

174), CDR3 (SEQ ID NO;

175) of antibody AM-23;

y. a light chain CDR1 (SEQ ID NO;

257), CDR2 (SEQ ID NO;

258), CDR3 (SEQ ID NO;

259) and a heavy chain CDR1 (SEQ ID NO;

176), CDR2 (SEQ ID NO;

177), CDR3 (SEQ ID NO;

178) of antibody AM-24;

z. a light chain CDR1 (SEQ ID NO;

260), CDR2 (SEQ ID NO;

261), CDR3 (SEQ ID NO;

262) and a heavy chain CDR1 (SEQ ID NO;

179), CDR2 (SEQ ID NO;

180), CDR3 (SEQ ID NO;

181) of antibody AM-25;

or

z.2. a light chain CDR1 (SEQ ID NO;

263), CDR2 (SEQ ID NO;

264), CDR3 (SEQ ID NO;

265) and a heavy chain CDR1 (SEQ ID NO;

182), CDR2 (SEQ ID NO;

183), CDR3 (SEQ ID NO;

184) of antibody AM-26;

wherein said polypeptide specifically binds IL-17 receptor A.

6. The method of claim 1, wherein said antibody comprises:

a) an antibody or an IL-17 receptor A binding fragment thereof comprising a heavy chain sequence of SEQ ID NO;

427 and a light chain sequence of SEQ ID NO;

429;

b) an antibody or an IL-17 receptor A binding fragment thereof comprising a light chain variable region sequence of SEQ ID NO;

40 and a heavy chain variable region sequence of SEQ ID NO;

14; and

c) an antibody or an IL-17 receptor A binding fragment thereof comprising a heavy chain CDR1 of SEQ ID NO;

146, a heavy chain CDR2 of SEQ ID NO;

147, a heavy chain CDR3 of SEQ ID NO;

148, a light chain CDR1 of SEQ ID NO;

224, a light chain CDR2 of SEQ ID NO;

225, and a light chain CDR3 of SEQ ID NO;

226.

7. The method of claim 1, wherein said antibody is selected from the group consisting of:

a. a human antibody;

b. a humanized antibody;

c. a chimeric antibody;

d. a monoclonal antibody;

e. an antigen-binding antibody fragment;

f. a single chain antibody;

g. a diabody;

h. a triabody;

i. a tetrabody;

j. a Fab fragment;

k. a F(ab′

)2 fragment;

l. an IgD antibody;

m. an IgE antibody;

n. an IgM antibody;

o. an IgG1 antibody;

p. an IgG2 antibody;

q. an IgG3 antibody; and

r. an IgG4 antibody.

8. The method of claim 1, further comprising performing surgery on said patient and/or administering radiation therapy and/or chemotherapy to said patient, wherein said surgery is performed and/or said radiation therapy and/or chemotherapy may be administered prior to, concurrent with, or subsequent to administration of said composition comprising said antibody.

9. The method of claim 8, wherein administration of said chemotherapy comprises administering a chemotherapeutic agent.